Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - NVO
10:30am, Wednesday, 05'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, f
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
10:22am, Wednesday, 05'th Mar 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo Nordisk To Contact Him Directly To Discuss Their Options If you purchased or acq
Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?
10:20am, Wednesday, 05'th Mar 2025
Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong demand for its GLP-1 drugs.
Novo Nordisk Boosts Wegovy Access With Lower Pricing and Home Delivery
10:15am, Wednesday, 05'th Mar 2025
On Wednesday, Novo Nordisk A/S NVO introduced NovoCare Pharmacy, a direct-to-patient delivery service to improve access to Wegovy (semaglutide) for cash-paying patients.
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordis
Novo Nordisk offers Wegovy for less than half the price through new direct-to-consumer pharmacy
08:49am, Wednesday, 05'th Mar 2025
Novo Nordisk will offer its weight loss drug Wegovy for less than half of its usual price per month through a new direct-to-consumer online pharmacy. The cash-pay offering is available to millions of
Novo Nordisk to offer lower-priced versions of Wegovy for cash-paying customers
08:11am, Wednesday, 05'th Mar 2025
Novo Nordisk said on Wednesday it would offer lower-priced doses of its weight loss drug Wegovy at a reduced cost of $499 per month for cash-paying customers.
NovoCare® Pharmacy provides direct-to-patient, convenient home shipments of all dose strengths of Wegovy® at a reduced cost of $499 per month for cash-paying patients While 90% of patients taking W
Down 39%. Is Novo Nordisk Stock a Buy on the Dip?
04:37am, Wednesday, 05'th Mar 2025
Novo Nordisk (NVO -2.09%) shareholders know all about the ups and downs of pharmaceutical stock investing. From the beginning of the coronavirus pandemic through the middle of last June, shares of Nov
The Zacks Analyst Blog Novo Nordisk, The Coca-Cola, Wells Fargo and Star Group
03:45am, Wednesday, 05'th Mar 2025
Novo Nordisk, The Coca-Cola, Wells Fargo and Star Group are included in this Analyst Blog.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in Novo Nordisk A/S Lawsuit - NVO
06:00pm, Tuesday, 04'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, f
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, 2022 and Dece
Lost Money on Novo Nordisk A/S(NVO)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
12:29pm, Tuesday, 04'th Mar 2025
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
South African watchdog probes Novo Nordisk and Sanofi over insulin
12:14pm, Tuesday, 04'th Mar 2025
South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive practices in the human insulin pen market, the authority said on Tuesday.
Shareholders That Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
10:30am, Tuesday, 04'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, f
